New drug BM230 enters first human trial for Hard-to-Treat cancers
NCT ID NCT06644300
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug, BM230, in people with advanced solid tumors, especially those linked to HER2. The study has two parts: first, finding the safest dose, then expanding to see how well it works. About 123 participants will be enrolled worldwide.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BM230
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that are HER2-related.
What could go wrong
This is a very early Phase 1 trial, so safety and effectiveness are not yet known. It may not lead to a proven treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan Unversity Zhongshan Hospital
RECRUITINGShanghai, Shanghai Municipality, China
-
Icon Cancer Centre - South Brisbane
RECRUITINGBrisbane, Queensland, 4101, Australia
-
Monash Health - Monash Medical Centre
RECRUITINGMonash, Victoria, Australia
-
Southern Oncology Clinical Research Unit
RECRUITINGAdelaide, South Australia, Australia
-
The first Affiliated Hospital of Bengbu Medical University
RECRUITINGBengbu, Anhui, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China